TKNO Stock Overview
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Alpha Teknova, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.70 |
| 52 Week High | US$4.27 |
| 52 Week Low | US$1.62 |
| Beta | 0.23 |
| 1 Month Change | -32.00% |
| 3 Month Change | -47.37% |
| 1 Year Change | -11.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.20% |
Recent News & Updates
Recent updates
Not Many Are Piling Into Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Yet As It Plummets 25%
Apr 24
Health Check: How Prudently Does Alpha Teknova (NASDAQ:TKNO) Use Debt?
Jan 22Some Analysts Just Cut Their Alpha Teknova, Inc. (NASDAQ:TKNO) Estimates
Aug 14Take Care Before Jumping Onto Alpha Teknova, Inc. (NASDAQ:TKNO) Even Though It's 30% Cheaper
Apr 17Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
May 14Shareholder Returns
| TKNO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -15.4% | 4.1% | 1.2% |
| 1Y | -11.9% | 4.7% | 24.9% |
Return vs Industry: TKNO underperformed the US Life Sciences industry which returned 4.7% over the past year.
Return vs Market: TKNO underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| TKNO volatility | |
|---|---|
| TKNO Average Weekly Movement | 12.1% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TKNO's share price has been volatile over the past 3 months.
Volatility Over Time: TKNO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 211 | Stephen Gunstream | www.teknova.com |
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
Alpha Teknova, Inc. Fundamentals Summary
| TKNO fundamental statistics | |
|---|---|
| Market cap | US$69.40m |
| Earnings (TTM) | -US$36.78m |
| Revenue (TTM) | US$36.68m |
1.9x
P/S Ratio-1.9x
P/E RatioIs TKNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TKNO income statement (TTM) | |
|---|---|
| Revenue | US$36.68m |
| Cost of Revenue | US$26.39m |
| Gross Profit | US$10.30m |
| Other Expenses | US$47.08m |
| Earnings | -US$36.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 28.07% |
| Net Profit Margin | -100.26% |
| Debt/Equity Ratio | 14.7% |
How did TKNO perform over the long term?
See historical performance and comparison